Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a medicare managed care population
References (38)
Glaucoma
Lancet.
(1999)- et al.
Causes of blindness and visual impairment in a population-based sample of US Hispanics
Ophthalmology
(2002) - et al.
Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
Ophthalmology
(2005) - et al.
Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study
Clin Ther
(2003) - et al.
Estimating log models: To transform or not to transform?
J Health Econ
(2001) - et al.
Persistency with latanoprost or timolol in primary open-angle glaucoma suspects
Am J Ophthalmol
(2004) - et al.
Patient persistency with ocular prostaglandin therapy: A population-based, retrospective study
Clin Ther
(2003) - et al.
Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a Medicare health maintenance organization
Am J Geriatr Pharmacother
(2003) - et al.
Racial differences in the cause-specific prevalence of blindness in east Baltimore
N Engl J Med.
(1991) - et al.
Models of open-angle glaucoma prevalence and incidence in the United States
Invest Ophthalmol Vis Sci.
(1997)
Glaucoma: Diagnosis and management
Postgrad Med J.
The Ocular Hypertension Treatment Study: Design and baseline description of the participants
Arch Ophthalmol
Prevalence of open-angle glaucoma among adults in the United States
Arch Ophthalmol
Management of glaucoma: Focus on pharmacological therapy
Drugs Aging
Costs of glaucoma medications
Am J Health Syst Pharm
Latanoprost vs combined therapy with timolol plus dorzolamide in open-angle glaucoma: A 24-month study
Ann Ophthalmol
Cited by (17)
Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results
2019, OphthalmologyCitation Excerpt :Although not a study end point, the use of medication before and after stent implantation in the study eye is relevant to the overall characterization of benefit, which is primarily based on the level of IOP reduction achieved after washout. Because patient compliance is known to decrease as the number of medications increases,42-44 and medications have drawbacks such as toxicities and costs,45-47 the proportions of eyes on 0, 1, or ≥2 medications are especially important indicators of treatment utility. In this study, 84% of treatment eyes meeting the primary study end point were not taking ocular hypotensive medications at 23 months, compared with 67% of control eyes.
Big data and ophthalmic research
2016, Survey of OphthalmologyCitation Excerpt :Nordstom and colleagues found half of patients had discontinued treatment by 6 months and that those taking prostaglandins were 60% less likely to discontinue compared to beta-blockers and carbonic anhydrase inhibitors.193 Other studies using claims data further support the findings from these studies,12,45,95,234,248,284,295,296 including one from Australia using national population-based pharmaceutical claims for 357,099 patients that confirmed superior persistency for prostaglandins.207 Pharmacoepidemiology studies using administrative data have their own unique limitations.228
Primary Open-Angle Glaucoma
2016, OphthalmologyPrimary Open-Angle Glaucoma Suspect
2016, OphthalmologyUse of glaucoma medications: State of the science and directions for observational research
2010, American Journal of OphthalmologyCitation Excerpt :Supplemental Table 2 provides details of how adherence and persistence were measured in each study. Rates of nonadherence ranged between 23% and 60% over 12 months.24,25,30–33 Rates of nonpersistence ranged between 30% and 95% at 1 year.29,33,39,43–48,50,52
Biotissue stent for supraciliary outflow in open-angle glaucoma patients: surgical procedure and first clinical results of an aqueous drainage biostent
2023, British Journal of Ophthalmology